Lilly publishes new study data for osteoporosis treatment Forteo
8 August 2012 11:32 in Pharmaceutical Company Product News
Lilly has published data from a new phase III clinical study that provides additional information about the use of its osteoporosis therapy Forteo.
The study compared the drug to risedronate in terms of its ability to reduce back pain in postmenopausal women with osteoporotic vertebral fractures over an 18-month period.
No difference was found in this regard, but Forteo was shown to offer benefits in certain exploratory measures, including greater increases in bone mineral density and fewer patients with new vertebral fractures.
The results of this study are significant due to the fact it compares two established osteoporosis medicines in a direct head-to-head design.
Dr Bruce Mitlak, distinguished medical fellow for Lilly's bone muscle and joint platform, said: "The results may help guide healthcare professionals in treating severe osteoporosis."
Last month, the company received European regulatory approval for Jentadueto, a new therapy for type 2 diabetes it has developed in association with Boehringer Ingelheim.
Other news stories from 08/08/2012
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency